Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
26/08/2025
Australian Prime Minister Albanese: The Australian Embassy in Tehran has suspended operations.
Latest
3 m ago
Highly popular stock Chunzhong Technology rapidly plunged and hit the daily limit near the close of trading.
3 m ago
HSBC Bank has upgraded its ratings for both the A-shares and H-shares of Great Wall Motors from "hold" to "buy".
3 m ago
HSBC Bank has upgraded its ratings on both A-shares and H-shares of Great Wall Motors from "hold" to "buy".
3 m ago
UBS released a research report stating that CanSino Biologics' performance in the second quarter slightly exceeded expectations, with revenue growth accelerating to 38% compared to 20% in the first quarter. Net losses narrowed to 2 million yuan, with a net loss of 13 million yuan in the first half of the year, a 94% decrease compared to the same period last year, which was lower than the bank's forecast of a loss of 31 million yuan. Management reiterated the full-year revenue guidance of 1 billion yuan. UBS reiterated its positive outlook on CanSino Biologics as the preferred stock in the vaccine sector, expecting its profit growth to accelerate and believing that its early pipeline products and licensing potential have not been fully reflected. The bank raised its target price from 47 Hong Kong dollars to 66.6 Hong Kong dollars, reaffirming a "buy" rating, and raised its earnings forecasts for 2025 to 2027 from 0.01, 1.16, and 2.39 yuan per share to 0.24, 1.16, and 2.55 yuan per share.
3 m ago
UBS: Raises CanSino Biologics' target price to HKD 66.6 and reiterates it as the top pick in the vaccine sector.
See all latest
